Síndrome hemolítico-urémico asociado al uso de gemcitabina: Caso clínico / Hemolytic-uremic syndrome associated with gemcitabine use: Report of one case
Rev. méd. Chile
;
141(6): 797-802, jun. 2013. ilus
Artículo
en Español
| LILACS
| ID: lil-687212
ABSTRACT
Gemcitabine is a widely used drug in the treatment of advanced pancreatic cancer and other malignancies. It is generally well tolerated and exceptionally its use has been associated with hemolytic-uremic syndrome, causing acute kidney injury, hipertension, chronic renal failure requiring dialysis, and death. We report a 60-year-old man with pancreatic carcinoma and regional lymph node invasion, whom after four months of therapy with gemcitabine and after dose number 11, suddenly developed an acute nephritic syndrome with moderate renal impairment, associated with severe anemia (hemoglobin 6.0 g/dL) and thrombocytopenia (20,000 mm³). Renal biopsy showed the classic findings of thrombotic micro angiopathy Gemcitabine was discontinued and renal function and hematological parameters gradually improved.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Desoxicitidina
/
Síndrome Hemolítico-Urémico
/
Antimetabolitos Antineoplásicos
Tipo de estudio:
Factores de riesgo
Límite:
Humanos
/
Masculino
Idioma:
Español
Revista:
Rev. méd. Chile
Asunto de la revista:
Medicina
Año:
2013
Tipo del documento:
Artículo
País de afiliación:
Chile
Institución/País de afiliación:
Hospital Dr. Gustavo Fricke/CL
Similares
MEDLINE
...
LILACS
LIS